SCHEMBL30788348

SCHEMBL30788348

CC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 4/20 0.54
▸ CALCR P30988 4/20 0.54
▸ HCRTR1 O43613 1/20 0.53
▸ HCRTR2 O43614 1/20 0.53
▸ C5AR1 P21730 2/20 0.53
▸ CXCR4 P61073 2/20 0.51
▸ TFPI P10646 2/20 0.51
▸ OPRM1 P35372 1/20 0.51
▸ OPRD1 P41143 1/20 0.51
▸ NMBR P28336 1/20 0.51
▸ GRPR P30550 1/20 0.51
▸ IL23R Q5VWK5 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788360 0.99 F2 (0.55) F2CALCRHCRTR1HCRTR2C5AR1
SCHEMBL30788338 0.97 F2 (0.58) F2CALCRHCRTR1HCRTR2C5AR1
SCHEMBL30788343 0.97 F2 (0.57) F2CALCRHCRTR1HCRTR2CXCR4
SCHEMBL30788336 0.97 F2 (0.57) F2CALCRHCRTR1HCRTR2CXCR4
SCHEMBL30788340 0.96 F2 (0.59) F2CALCRHCRTR1HCRTR2CXCR4
SCHEMBL30788366 0.96 C5AR1 (0.58) C5AR1CXCR4TFPIOPRM1IL23R
SCHEMBL30788369 0.95 C5AR1 (0.57) C5AR1CXCR4TFPIOPRM1IL23R
SCHEMBL30788341 0.94 CALCR (0.58) F2CALCRHCRTR1HCRTR2C5AR1
SCHEMBL30788353 0.92 CALCR (0.60) F2CALCRHCRTR1HCRTR2C5AR1
SCHEMBL30788359 0.92 CTSL (0.56) F2CALCRC5AR1CXCR4TFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-05-02 — — US disclosed
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-04-18 — — US disclosed
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY GLO PHARMA, INC. 2024-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, PLIN3 F2 3370/4885CALCR 3447/4885HCRTR1 3154/4885
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNB1, CHRNG, CHRNA1 F2 2151/4885CALCR 128/4885HCRTR1 528/4885
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, LIPE F2 3567/4885CALCR 4453/4885HCRTR1 3635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback